Preference for a Prefilled Syringe or Smartject Device for Delivering SIMPONI (Golimumab) in Patients Suffering From Moderate to Severe Ulcerative Colitis

Trial Profile

Preference for a Prefilled Syringe or Smartject Device for Delivering SIMPONI (Golimumab) in Patients Suffering From Moderate to Severe Ulcerative Colitis

Completed
Phase of Trial: Phase IV

Latest Information Update: 13 Apr 2017

At a glance

  • Drugs Golimumab (Primary)
  • Indications Ulcerative colitis
  • Focus Therapeutic Use
  • Acronyms SMART
  • Sponsors Merck Sharp & Dohme
  • Most Recent Events

    • 14 Oct 2015 Status changed from active, no longer recruiting to completed, as reported by ClinicalTrials.gov record.
    • 23 Sep 2015 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov record.
    • 16 Sep 2015 Planned End Date changed from 1 Sep 2015 to 1 Oct 2015 as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top